Cargando…

Molecular Mechanism Biomarkers Predict Diagnosis in Schizophrenia and Schizoaffective Psychosis, with Implications for Treatment

Diagnostic uncertainty and relapse rates in schizophrenia and schizoaffective disorder are relatively high, indicating the potential involvement of other pathological mechanisms that could serve as diagnostic indicators to be targeted for adjunctive treatment. This study aimed to seek objective evid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fryar-Williams, Stephanie, Tucker, Graeme, Strobel, Jörg, Huang, Yichao, Clements, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10650772/ https://www.ncbi.nlm.nih.gov/pubmed/37958826 http://dx.doi.org/10.3390/ijms242115845

Ejemplares similares

Molecular Mechanisms Provide a Landscape for Biomarker Selection for Schizophrenia and Schizoaffective Psychosis
por: Fryar-Williams, Stephanie, et al.
Publicado: (2023)

Biomarkers of a five-domain translational substrate for schizophrenia and schizoaffective psychosis
por: Fryar-Williams, Stephanie, et al.
Publicado: (2015)

Fundamental Role of Methylenetetrahydrofolate Reductase 677 C → T Genotype and Flavin Compounds in Biochemical Phenotypes for Schizophrenia and Schizoaffective Psychosis
por: Fryar-Williams, Stephanie
Publicado: (2016)

Biomarker Case-Detection and Prediction with Potential for Functional Psychosis Screening: Development and Validation of a Model Related to Biochemistry, Sensory Neural Timing and End Organ Performance
por: Fryar-Williams, Stephanie, et al.
Publicado: (2016)

Carbamazepine and psychotherapy in the treatment of schizoaffective psychosis.
por: Cegalis, J. A., et al.
Publicado: (1985)

Structured lifestyle education for people with schizophrenia, schizoaffective disorder and first-episode psychosis (STEPWISE): randomised controlled trial
por: Holt, Richard I. G., et al.
Publicado: (2019)

Neurophysiological Distinction between Schizophrenia and Schizoaffective Disorder
por: Mathalon, Daniel H., et al.
Publicado: (2010)

Alcohol Use Disorder and Schizophrenia or Schizoaffective Disorder
por: Archibald, Luke, et al.
Publicado: (2019)

SCHIZOAFFECTIVE DISORDER : CONSISTENCY OF DIAGNOSIS
por: Shrivastava, Amresh, et al.
Publicado: (1999)

Liraglutide and the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first-episode psychosis: protocol for a pilot trial
por: Whicher, Clare Alexandra, et al.
Publicado: (2019)

Efficacy and tolerability of Aripiprazole in Patients with Schizophrenia & Schizoaffective Disorders
por: Andrade, Chittaranjan
Publicado: (2004)

Efficacy and Tolerability of Aripiprazole in Patients with Schizophrenia & Schizoaffective Disorders
por: Chavda, R.K., et al.
Publicado: (2004)

Measuring Emotional Awareness in Patients With Schizophrenia and Schizoaffective Disorders
por: Maaßen, Eva, et al.
Publicado: (2021)

Cardiovascular Risk for Patients With and Without Schizophrenia, Schizoaffective Disorder, or Bipolar Disorder
por: Rossom, Rebecca C., et al.
Publicado: (2022)

5.3 EVIDENCE ON A TRANSDIAGNOSTIC PSYCHOSIS SPECTRUM OF SCHIZOPHRENIA, SCHIZOAFFECTIVE AND PSYCHOTIC BIPOLAR DISORDER IN THE BIPOLAR-SCHIZOPHRENIA NETWORK ON INTERMEDIATE PHENOTYPES (B-SNIP)
por: Reininghaus, Ulrich, et al.
Publicado: (2018)

The continuing story of schizophrenia and schizoaffective disorder: One condition or two?
por: Hartman, Leah I., et al.
Publicado: (2019)

Religious Coping Strategies for Religious Patients with Schizophrenia and Schizoaffective Disorder
por: Gedevani, E., et al.
Publicado: (2022)

The use of technologies and social media in patients with schizophrenia and schizoaffective disorder
por: Elleuch, O., et al.
Publicado: (2022)

Clinical factors affecting functioning in patients with schizophrenia or schizoaffective disorder
por: Neily, C., et al.
Publicado: (2022)

Reducing weight gain in people with schizophrenia, schizoaffective disorder, and first episode psychosis: describing the process of developing the STructured lifestyle Education for People With SchizophrEnia (STEPWISE) intervention
por: Carey, Marian E., et al.
Publicado: (2018)

microRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder
por: Perkins, Diana O, et al.
Publicado: (2007)

Social function in schizophrenia and schizoaffective disorder: Associations with personality, symptoms and neurocognition
por: Lysaker, Paul H, et al.
Publicado: (2004)

Trauma and Posttraumatic Stress Disorder (PTSD) in Patients with Schizophrenia or Schizoaffective Disorder
por: Lommen, Miriam J. J., et al.
Publicado: (2009)

Blonanserin-induced Mood Alteration in Schizophrenia and Schizoaffective Disorder: Two Cases
por: Min, Aran, et al.
Publicado: (2013)

Distinctive transcriptome alterations of prefrontal pyramidal neurons in schizophrenia and schizoaffective disorder
por: Arion, Dominique, et al.
Publicado: (2015)

The Effectiveness of Cross-Tapering Switching to Ziprasidone in Patients with Schizophrenia or Schizoaffective Disorder
por: Ko, Young-Hoon, et al.
Publicado: (2014)

Evidence for Distinguishable Treatment Costs among Paranoid Schizophrenia and Schizoaffective Disorder
por: Hirjak, Dusan, et al.
Publicado: (2016)

Brain structural changes in schizoaffective disorder compared to schizophrenia and bipolar disorder
por: Amann, B. L., et al.
Publicado: (2015)

Study of the Effect of Memantine on Negative Sign in Patients with Schizophrenia and Schizoaffective Disorders
por: Tavakoli-Ardakani, Maria, et al.
Publicado: (2018)

Impairment in delay discounting in schizophrenia and schizoaffective disorder but not primary mood disorders
por: Brown, Hannah E., et al.
Publicado: (2018)

Risk of readmission in patients with schizophrenia and schizoaffective disorder newly prescribed clozapine
por: Kesserwani, Jad, et al.
Publicado: (2019)

Social and Neurocognitive Deficits in Remitted Patients with Schizophrenia, Schizoaffective and Bipolar Disorder
por: Dehelean, Liana, et al.
Publicado: (2021)

Testing the hypothesis of subtypes of nonadherence in schizophrenia and schizoaffective disorder: A prospective study
por: Vega, Dulcinea, et al.
Publicado: (2020)

Reaction Time and Visual Memory in Connection with Alcohol Use in Schizophrenia and Schizoaffective Disorder
por: Mazumder, Atiqul Haq, et al.
Publicado: (2021)

The recovery of homicidal people diagnosed with schizophrenia and schizoaffective disorder—An interpretative phenomenological analysis
por: Kovács, Asztrik, et al.
Publicado: (2023)

Hummingbird Study: Results from an Exploratory Trial Assessing the Performance and Acceptance of a Digital Medicine System in Adults with Schizophrenia, Schizoaffective Disorder, or First-Episode Psychosis
por: Fowler, J Corey, et al.
Publicado: (2021)

Implication of Electrophysiological Biomarkers in Psychosis: Focusing on Diagnosis and Treatment Response
por: Lee, Ho Sung, et al.
Publicado: (2022)

Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder
por: Stauffer, Virginia L, et al.
Publicado: (2010)

Criteria for symptom remission revisited: a study of patients affected by schizophrenia and schizoaffective disorders
por: Pinna, Federica, et al.
Publicado: (2013)

Using blood cytokine measures to define high inflammatory biotype of schizophrenia and schizoaffective disorder
por: Boerrigter, Danny, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_pm0dn9ruarqb76f5p8apue2mg5